Replacement of intravenous administration of anti‐D by subcutaneous administration in patients with autoimmune thrombocytopenia

Intravenous (IV) administration of anti‐D in patients with autoimmune thrombocytopenia (AITP) may result in severe hemolysis and even death. Over a 3‐year period, we gave anti‐D only subcutaneously (SC), and none of our patients have developed any acute adverse reaction. Most importantly, SC delivery of anti‐D produces largely the same beneficial effect as obtained by IV anti‐D. We recommend replacement of IV administration of anti‐D by SC administration in AITP. Pediatr Blood Cancer 2006;47:721–722. © 2006 Wiley‐Liss, Inc.